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ABSTRACT Nonmelanoma skin cancers (NMSC), basal cell carcinoma 
(BCC), and cutaneous squamous cell carcinoma (cSCC) are the most 
common malignancies worldwide with a prevalence of epidemic pro-
portions and continually rising global incidence rates, associated with 
increased morbidity rates and significant economic burden of their 
management. Although treatable cancers with low rates of metastasis 
and mortality, NMSCs reach an incurable state in small proportion of 
patients, becoming advanced, unresectable, or metastatic. Until recent 
years, patients with these conditions were considered for palliative ra-
diotherapy and/or classical chemotherapies, which offer modest clini-
cal benefit. Based on better understanding of the pathogenesis of these 
cancers, novel targeted therapies have been developed. We review novel 
systemic approaches for the treatment of aggressive forms of BCCs and 
cSCCs, with special emphasis on approved targeted molecular therapies 
and immunotherapies.
KEYWORDS: nonmelanoma skin cancer, advanced basal cell carcinoma, 
advanced cutaneous squamous cell carcinoma, hedgehog pathway in-
hibitors, immune checkpoint inhibitors
INTRODUCTION
Basal cell (BCC) and cutaneous squamous cell car-
cinomas (cSCC), jointly referred to as nonmelanoma 
skin cancers (NMSC), are the most commonly diag-
nosed malignant neoplasms in Caucasians in most 
countries around the world (1,2), with BCC being the 
most common type and comprising approximately 
80% of these NMSCs (3,4). Generally, the incidence 
and mortality rates of NMSCs are difficult to establish 
in many countries since they are usually excluded 
from cancer registries and death is uncommon. 
It is well known that incidence rates of these tu-
mors are increasing worldwide (3,4). It is estimated 
that one in five Americans will develop skin cancer 
in their lifetime (1). According to one estimate in the 
US, about 5.4 million NMSCs are diagnosed each year, 
occurring in about 3.3 million Americans, indicating 
that some people have more than one (3,5). Incidence 
rates of BCC in the US have risen by approximately 2% 
per year, and there are significant increases among 
women and individuals younger than 40 years in 
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whom the incidence doubled, while the incidence of 
cSCC in individuals younger than 40 years tripled (3,6-
9). In western Europe, incidence rates of BCC have 
risen 2-3 times in the last few decades (2).
One study has estimated a diagnosis rate of 15–35 
cSCC per 100 000 people, with an average increase of 
2-4% per year (3). In the United States, up to 420 000 
new cases of cSCC have been estimated to occur in 
2012 (6). Australia has the highest incidence of cSCC 
in the world, with over 300 000 patients diagnosed 
per year (3).
NMSCs are treatable cancers and have low rates 
of metastasis and mortality compared with other 
malignomas; however, their high incidence rates and 
treatment costs contribute significantly to the rising 
economic burden of health care, making it the fifth 
most costly cancer in the US (4,10). 
Metastatic disease is rare, occurring in only 
0.0028-0.55% of BCCs, and mortality rate is quite low 
(11-13). However, more locally aggressive BCCs cause 
significant morbidity (14). Although only 5% of cSCC 
will become locally advanced, recur, or metastasize, 
this still represents a significant problem (6,15). They 
are associated with significant morbidity and are re-
sponsible for the majority of NMSC deaths (16). Their 
overall mortality rate is estimated between 1 and 5% 
(15,17).
Approximately 2,000 people in the US die each 
year from these cancers, however it is thought that 
this rate has been dropping in recent years due to im-
proved treatment options (5).  
Risk factors for NMSC include chronic sun exposure, 
longer life expectancy, fair skin type, genetic disorders 
(e.g. Gorlin syndrome, xeroderma pigmentosum), his-
tory of NMSC, and immunosuppression (5,14,18,19). 
Exposure to ultraviolet (UV) light, particularly UVB, 
represents the greatest risk factor for the develop-
ment of NMSC with a clear mutational signature of UV 
radiation (20,21). A history of blistering sunburns in 
younger age and exposure to UV radiation early in life 
as well as intermittently throughout life have been as-
sociated with BCC (22,23). In the past decade, indoor 
tanning has emerged as a significant risk factor for 
skin cancer, including early-onset BCC (24,25). 
Chronically immunosuppressed patients (e.g. 
solid organ transplant recipients) are at high risk not 
only for NMSC but also for more aggressive pheno-
types of these skin cancers due to impaired immu-
nosurveillance (26,27). The risk of developing cSCC in 
this group of patients is 65 to 250 times as high as the 
risk in the general population (26-28), and the risk of 
BCC is significantly increased at a factor of 7 to 20 as 
compared with the normal population (29).
For the vast majority of NMSCs (more than 95%), 
surgery is the curative treatment of choice as it pro-
vides the best means of controlling that the entire 
tumor is removed (30). Besides excisional surgery as 
the gold standard, Mohs micrographic surgery and 
ablative methods can also be used.
Nonsurgical methods represent a therapy option 
for certain patients, as cure rates approach those 
provided by surgery in many cases, and other advan-
tages are lower overall costs and more cosmetically 
acceptable outcomes (31,32).
These methods include superficial field therapies, 
such as photodynamic therapy, 5-fluorouracil (5-
FU), imiquimod, and intralesional interferon alfa-2b, 
for low-risk, superficial tumors, as well as primary or 
adjuvant radiotherapy for patients not amenable to 
surgery.
However, in a small percentage of patients, the tu-
mor reaches an incurable state because it becomes 
metastatic or locally advanced and is no longer ame-
nable to surgery or radiotherapy. Advanced cSCC and 
advanced BCC are two conditions that involve these 
two incurable situations, and patients with these con-
ditions are considered for palliative systemic therapy. 
Chemotherapy has been used to treat these patients, 
although no standard chemotherapeutic regimen ex-
ists and it remains unknown if any of it can provide 
long-term survival or quality-of-life benefits.
In recent years, knowledge of the pathogenesis of 
NMSCs has led to the development of improved ther-
apy options for advanced cases. Herein we review re-
cently available insights concerning the treatment of 
locally advanced and metastatic BCC and cSCC, with 
a special emphasis on novel targeted therapy and im-
munotherapy. 
Advanced BCC
Although locally destructive with a low rate of 
metastasis and mortality, BCC can progress to an ad-
vanced stage in a small portion of patients, encom-
passing metastatic BCC (mBCC) and locally advanced 
BCC (laBCC), whereby becoming more difficult to 
treat (5,14,33,34). Metastatic disease occurs more fre-
quently with large, untreated and aggressive primary 
tumors or with recurrent tumors (11,35,36). The most 
frequent sites of metastasis are the bone, lung, liver, 
and regional lymph nodes (11,36). It is estimated that 
once metastases develop the median overall survival 
is between 8 months and 7.3 years, with recently im-
proving survival rates due to improved treatment op-
tions (12,13,36).
Large, aggressive or recurrent tumors or those 
that penetrate deeper into the underlying skin and 
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surrounding tissues are generally considered laBCC 
(33,37). When located in a difficult-to-treat areas (e.g. 
periorbital), those kinds of tumors can be challeng-
ing for effective surgery without causing significant 
morbidity, loss of function, or disfigurement, and may 
not be amenable to radiotherapy. LaBCCs are also as-
sociated with high recurrence risk (33,37).
Since there is no widely accepted definition of 
laBCC, several multidisciplinary groups of experts 
have recently proposed guidelines for defining laBCC 
in an attempt to facilitate proper diagnosis and effec-
tive treatment (33,38). According to one UK group, 
BCCs staged ≥II according to the American Joint 
Committee on Cancer guidelines are considered lo-
cally advanced (39), as well as those in whom current 
treatment options are contraindicated by disease- 
(tumor size, location, number, histological subtype, 
and recurrent disease) or patient-driven factors (age, 
effects on quality of life, patient opinion on therapy, 
genodermatosis, and immunosuppression) (33).
Management of patients with aBCC should in-
clude physicians with experience in this field and 
whenever possible a multidisciplinary team made 
of dermatologists, Mohs surgeons, head and neck 
surgeons, plastic surgeons, oncologists, radiologists, 
and pathologists, to help determine the best course 
of treatment (33,40).
Up to now, treatment options for patients with 
these tumors have been limited to surgery, radio-
therapy, and consideration of chemotherapy, since 
there is no evidence of consistent efficacy with any 
chemotherapeutic regimen (41-43). However, rising 
knowledge of the pathogenesis of BCCs in recent 
years, specifically comprehension of the Hedgehog 
(Hh) pathway, made a leap towards development of 
inhibitors targeting this pathway which have shown a 
great promise in this difficult-to-treat disease.
Hedgehog pathway and targeted  
inhibitors
The Hh signaling pathway is an evolutionary 
conserved pathway of signal transmission from the 
cell membrane to the nucleus (44). It is essential for 
cell differentiation, proliferation, and tissue pattern-
ing during embryonic development (45,46). The Hh 
pathway is mostly inactive or poorly active in adults 
(44) and is involved in the maintenance of certain tis-
sues and stem cells under normal conditions (46,47). 
However, aberrant activation of the Hh pathway has 
been detected in the development and promotion 
of several tumor types, including BCC, medulloblas-
toma, and gastrointestinal carcinomas (34). The sig-
naling Hh pathway includes the ligands, i.e. three ho-
mologues of the Hh gene, Sonic (Shh), Desert (Dhh) 
and Indian (Ihh), patched receptors (PTCH1, PTCH 2), 
signal transducer smoothened (SMO), and glioma-
associated oncogene (Gli) transcription factors (Gli1, 
Gli2, Gli3) (34). Signaling is initiated when 1 of the 3 
Hh ligands binds to the extracellular region of the 
PTCH1, thereby relieving the inhibition that unbound 
PTCH1 exerts on the SMO (48-51). SMO can then acti-
vate downstream signaling that culminates with the 
expression of the Gli transcription factors that pro-
mote proliferation, survival, and differentiation, and 
represent the key genes involved in BCC tumorogen-
esis (14,52). BCC was first to be associated with aber-
rant Hh signaling when mutations in the PTCH1 gene 
were identified as the driving mutations in patients 
with Gorlin syndrome, often having numerous BCCs 
(53-55). Most spontaneous BCCs were found to have 
inactivating mutations in PTCH1 in 85-90% of cases 
and activating mutations in SMO in about 10% of 
cases (52-54,56,57). 
Therefore, several of the small-molecule targeted 
therapies have focused on SMO inhibition. 
Vismodegib (GDC-0449), a small-molecule com-
pound optimized for selective and potent SMO inhi-
bition, was the first Hh pathway inhibitor (HPI) which 
demonstrated clinical efficacy in patients with aBCC 
(58,59). It was followed by sonidegib (LDE225), an-
other SMO inhibitor, with efficacy and safety profile 
similar to that of vismodegib (60,61). Additional SMO 
inhibitors, such as itraconazole, LY2940680, BMS-
833923 and PF-044449913, are in various stages of 
clinical development for the treatment of patients 
with aBCC and other advanced cancers (62-64).
Vismodegib
Vismodegib is a first-in-class orally bioavailable 
agent which gained Food and Drug Administration 
(FDA) approval in 2012 for use in adult patients with 
mBCC or laBCC that has recurred following surgery or 
who are not candidates for surgery or radiotherapy 
(51,65,66). In the initial phase I trial by Von Hoff et al. 
that evaluated dose and toxicity of the drug and tu-
mor responses, 33 patients with aBCC (18 with mBCC 
and 15 with laBCC) were enrolled and treated with 
vismodegib at one of three doses (150, 270 or 540 mg 
daily) (58). The median duration of treatment was 9.8 
months and the objective response rate (ORR) was 
58% (18 out of 33 patients responded); 2 patients had 
a complete response (CR), defined as 100% regres-
sion of the visible/palpable lesions; 6 patients had a 
partial response (PR), defined as more than 50% re-
duction in tumor diameter (58). The median duration 
of response (DOR) was 12.8 months. Of the patients 
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who did not respond, 11 had stable disease (SD) and 
4 had progressive disease (PD). Molecular evaluation 
of tumor tissue was been included in the study and 
found elevated Gli mRNA levels in tissue samples of 
some patients with PD, raising the question of pos-
sible resistance (58).
Approval of vismodegib 150 mg once daily was 
granted based on the clinical efficacy demonstrat-
ed in the ERIVANCE phase II study by Sekulic et al. 
(59,65,66). This international, 2-cohort, single-arm 
trial enrolled 104 patients, 33 patients with mBCC and 
71 patients with laBCC, who were treated with vismo-
degib 150 mg daily (59,67). 
Results of the primary analysis found that most 
patients experienced tumor shrinkage in the laBCC 
cohort: ORR (CR+PR) was 43%, CR was achieved in 
21% (defined as absence of BCC per histological as-
sessment) and PR achieved in 22% ( ≥30% decrease 
of target lesions). SD was observed in 38%, whereas 
13% had PD (≥20% increase in target lesion size or 
new ulceration/lesion). The median DOR in this co-
hort was 7.6 months, and the median progression-
free survival (PFS) was 9.5 months.
In the mBCC cohort, the ORR was 30%; all respons-
es were PRs. SD and PD were reported in 64% and 3%, 
respectively. Most patients with mBCC (73%) experi-
enced tumor shrinkage. The median DOR was 7.6 
months and the median PFS was 9.5 months (59,67).
The ERIVANCE study evaluated safety using the 
Common Terminology Criteria for Adverse Events 
(CTCAE) v3.0 (59,68). In the primary analysis, the me-
dian duration of exposure to vismodegib was about 
10 months in both cohorts of patients (59). All pa-
tients experienced ≥1 adverse events (AE), but most 
of them had only grade 1/2 AEs (67). The most com-
mon AEs were muscle spasms (68%), alopecia (63%), 
dysgeusia (51%), decreased weight (46%), fatigue 
(36%), nausea (29%), decreased appetite (23%), and 
diarrhea (22%). Thirteen patients (12%) discontin-
ued treatment due to AEs, particularly due to muscle 
spasms. More severe AEs were reported in 25% of pa-
tients. Sixteen patients died by the time of primary 
analysis, but none of the deaths were considered 
related to vismodegib. The median duration of expo-
sure in all patients was 12.9 months (67).
The safety and efficacy of vismodegib 150 mg 
once daily was assessed in 2 additional studies, an 
expanded access study (69) and the Safety Events in 
Vismodegib (STEVIE) study (70). 
The expanded access study was an open-label, 
2-cohort, multicenter US study which enrolled 119 
patients, 62 patients with laBCC and 57 patients with 
mBCC (69). The median duration of exposure was 
only 5.5 months due to earlier termination of study 
appearing after FDA approval of vismodegib. In the 
laBCC cohort, the ORR was 46%, and in the mBCC co-
hort ORR was 31%. The safety profile of vismodegib 
was similar to that observed in ERIVANCE; most pa-
tients experienced at least one AE, primarily graded 
1/2. The most common AEs were muscle spasms 
(71%), dysgeusia (71%), alopecia (58%), and diarrhea 
(25%) (69).
STEVIE, the largest vismodegib trial to date, was 
an open-label, multicenter study that evaluated safe-
ty (primary objective) and efficacy of vismodegib in 
499 patients (468 patients with laBCC and 31 patients 
with mBCC) who were followed for ≥ 12 months (70). 
ORR was observed in 66.7% of patients with laBCC 
and 37.9% of those with mBCC. The median time to 
response was 2.7 months and the median DOR was 
22.7 months. Most patients experienced ≥1 AE, and 
the most common AEs were similar to those report-
ed in ERIVANCE, i.e. muscle spasms (64%), alopecia 
(62%), dysgeusia (54%), weight loss (33%), asthenia 
(28%), decreased appetite (25%), and ageusia (22%). 
36% of patients discontinued therapy due to AEs 
(59,67,70). Other more serious AEs include significant 
fatigue, hyponatremia, hypocalcemia, and atrial fibril-
lation (71).
Sonidegib
Sonidegib gained approval in 2015 in the US and 
Europe for the treatment of adults with laBCC who 
are not candidates for curative surgery or radiothera-
py (72). In Switzerland and Australia, sonidegib is also 
approved for the treatment of patients with mBCC 
(73,74). Approval of sonidegib 200 mg once daily was 
granted based on efficacy and safety demonstrat-
ed in the international, randomized, double-blind, 
phase II Basal Cell Carcinoma Outcomes With LDE225 
Treatment (BOLT) study (61,72-74). The BOLT study 
included long-term follow-up data of 194 patients 
with laBCC and 36 patients with mBCC, random-
ized 1:2 into the sonidegib 200 mg and 800 mg daily 
treatment arms (61). More patients were random-
ized to receive sonidegib 800 mg based on phase 1 
data, indicating that the higher dose would provide 
better efficacy (60). However, in BOLT sonidegib 200 
mg demonstrated a better benefit-risk profile than 
sonidegib 800 mg (61); therefore further discus-
sion has focused primarily on the 200-mg dose. The 
median follow-up in this study was 13.9 months. In 
primary analysis the ORR in patients with laBCC was 
47% with CRs, PRs, SD, and PD reported in 3%, 44%, 
44%, and 1.5 % of patients, respectively (61,75). Most 
patients experienced reduction in target lesion size. 
Similar efficacy of sonidegib was observed in patients 
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with aggressive and nonaggressive histological sub-
types of laBCC (75).
The ORR in patients with mBCC was 15%, including 
2 patients with PRs (61). Disease control (CR+PR+SD) 
was observed in 92% of patients and most of them 
experienced tumor reduction. The median PFS was 
13.1 months, and PD or death was reported in only 
4 patients (61).
In BOLT 12-month analysis, sonidegib continued 
to demonstrate sustained and meaningful tumor re-
sponses (75).
In the primary analysis, the most common AEs 
(200/800 mg; any grade) evaluated per CTCAE v4.03, 
which generally occurred more often with the 800-
mg dose, were muscle spasms (49%/67%), alopecia 
(43%/55%), dysgeusia (38%/59%), nausea (33%/45%), 
elevated creatine kinase (CK) levels (29%/37%), fa-
tigue (29%/36%), weight loss (27%/38%), and diar-
rhea (24%/22%) (61).
The most frequently reported grade 3/4 AEs 
(200/800 mg) were elevated CK and lipase levels. 
Discontinuation of treatment was observed in 20% 
and 32% of patients in the 200 mg and 800 mg arms, 
respectively, mainly due to muscle spasms, dysgeu-
sia and weight loss. The most common serious AEs 
(200/800 mg) were elevated CK levels and rhabdo-
myolysis (61). In the primary analysis, 4 patients re-
ceiving sonidegib 800 mg died while on treatment, 
but none of these deaths were considered related to 
treatment (61).
Generally, the safety profile of sonidegib was simi-
lar to that of vismodegib (59,61,67,69,70), indicating 
that many of the AEs, such as muscle spasms and dys-
geusia, are class effects (40). Both drugs carry a risk of 
severe birth defects or fetal death when a pregnant 
woman is exposed to them (40).
Other hedgehog pathway inhibitors
Other HPIs, such as itraconazole, BMS-833923, ta-
ladegib (LY2940680), and PF-04449913 are in various 
stages of clinical development; however no clinical 
data exists for treatment in aBCC (62-64). Itraconazole, a 
commonly used antifungal agent, demonstrated some 
efficacy and safety in patients with sporadic BCCs in an 
exploratory phase 2 study with PRs and SD reached in 
4 patients (21%) each (62). On average, patients who 
received this drug had a 24% reduction in lesion area. 
AEs were generally mild and reversible (62).
Hedgehog pathway resistance and other 
implications
Although most patients with aBCC achieve disease 
control with HPI therapy, some of the patients are in-
trinsically resistant to treatment and others become 
resistant during it (59,61,67,76-79). In other words, 
primary and secondary drug resistances to HPIs are 
different (78,79). New heterozygous missense SMO 
mutations were sequenced in recurrent BCC tissues 
resistant to vismodegib (78,79). In cases of secondary 
resistance, isolated SMO mutations were not pres-
ent in primary tumors that originally responded to 
treatment, but in distinct recurrent BCC nodules, sug-
gesting a heterogenous and dynamic mechanism of 
resistance that can rapidly arise in recurrent tumor 
tissue (79). In case of primary resistance, genotyping 
patient tumors could identify patients with muta-
tions and help avoid unnecessary treatment with a 
SMO inhibitor (34).
More interestingly, a resistance to sonidegib was 
also observed in a study of 9 patients with aBCC resis-
tant to vismodegib, suggesting that chemoresistance 
can occur between different SMO inhibitors (80).
Disease recurrence in patients who initially re-
sponded to HPI treatment may be due to residual 
tumor cells escaping the cytotoxic effects of HPI 
therapy or becoming resistant to it (77). A study that 
analysed tumor biopsy specimens from patients with 
laBCC treated with vismodegib and who experienced 
recurrence following an initial response, found reac-
tivation of Hh signal pathway, often associated with 
SMO mutations in or near the drug-binding pocket 
(inhibiting vismodegib binding) or in other SMO ar-
eas (likely contributing to SMO activation) (77). Thus, 
recurrence was associated with the proliferation of re-
sistant, possibly preexisting subclones that emerged 
after the elimination of larger HPI-sensitive cell popu-
lations (77).
Given the above, alternative treatment strate-
gies may prove beneficial in patients with aBCC. One 
approach is to target Hh signaling downstream of 
SMO in order to bypass acquired mutations affect-
ing SMO inhibitor binding, i.e. through inhibition 
of the Gli transcription factors. GANT61 is an inhibi-
tor of Gli1/2 transcriptional activity that has shown 
promising preclinical results in numerous tumor 
types (81-83).
Anti-programmed death-1 (PD-1) immunothera-
py may be another emerging treatment option. One 
case report described achievement of near complete 
remission of HPI-resistant mBCC following anti-PD-1 
antibody treatment (84).
Combination of HPIs and surgery (neoadjuvant 
therapy) could also prove beneficial for some patients 
to help achieve long-term responses and reduce the 
disfigurement associated with complex surgeries 
(40,85).
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Patients on HPI therapy often discontinue treat-
ment due to mostly low-grade AEs and many of them 
consequently experience recurrence (61,67). Manag-
ing AEs and educating patients in order to prolong 
their time on therapy could help achieve deeper and 
more long-lasting responses, with intermittent HPI 
dosing schedules being one potential option (40,71).
In conclusion, HPIs have proven to be an effec-
tive treatment option for patients with aBCC. While 
the results of this treatment have been promising, 
there still remain questions regarding durability of 
the response, long-term tolerability of AEs, and more 
importantly acquisition of resistant mutations over 
time. 
Advanced cSCC
In a small percentage of patients, cSCC reaches an 
incurable state referred to as advanced cSCC, because 
it becomes metastatic or locally advanced and is no 
longer amenable to surgery or radiotherapy (86). Sev-
eral risk factors have been identified for recurrence and 
metastasis, such as large tumor diameter, poor histo-
logical differentiation, and immunosuppression (16).
Patients with this condition are considered for pal-
liative radiotherapy and/or classical chemotherapies, 
which offer modest clinical benefit (87-89). Platin de-
rivates, i.e. cisplatin or carboplatin, have been com-
monly used as the first-line molecules for advanced 
unresectable or metastatic cSCC but with limited 
clinical trial experience (88,90). Other molecules used 
for either advanced or metastatic disease include 5-
FU, bleomycin, methotrexate, adriamycin, taxanes, 
gemcitabine, or ifosfamide alone or in combination 
(19), with RRs for single agents varying widely from 
17 to 78% (91,92). Platins and 5-FU are often used as 
palliative treatment alone or in combination with ra-
diotherapy (92). Combinations of cisplatin with either 
5-FU, doxorubicin, or bleomycin have demonstrated 
some degree of efficacy, achieving CR in some cases 
(93). Polychemotherapies seem more effective than 
monochemotherapy but result in more side-effects 
and poor tolerance. There is currently no standard 
treatment of metastatic disease (94).
Newer treatment options with improved response 
rates are based on better understanding of the patho-
genesis of cSCC. 
Epidermal growth factor receptor (EGFR) and its 
family members are often overexpressed or activated 
in human carcinomas, including cSCC, and may con-
tribute to enhance uncontrolled proliferation (94). 
Previous studies have shown that up to 80% of cSCC 
and 100% of metastatic cSCC express EGFR (95). 
Additionally, recent studies have indicated that 
cSCC is highly mutated, displaying a complex genetic 
background (96). The high mutation burden of the 
tumor, i.e. increased neoantigen expression due to 
chronic skin damage from UV light and dramatically 
increased risk of cSCC among immunosuppressed 
people pointed to an important role of immunosur-
veillance for preventing cSCC in immunocompetent 
people (97-99). Therefore, cSCC has the clinical and 
molecular features of a tumor that is likely to be re-
sponsive to systemic immunotherapy with check-
point inhibitors (100-102).
Immune checkpoint inhibitors, in particular 
monoclonal antibodies, are able to activate a T-cell-
specific immune response and have shown impres-
sive success in some adult malignancies, such as ma-
lignant melanoma, non-small-cell lung cancer, head 
and neck SCCs, and recently also in cSCC (94).
Cemiplimab is a high-affinity, highly potent hu-
man monoclonal antibody directed against PD-1 
receptor expressed on activated T and B lympho-
cytes and macrophages, blocking its interaction with 
PD-ligand 1 (PD-L1) and 2 (PD-L2) on the surface of 
tumor (103,104). Binding of the PD-1 receptor to PD-
L1 and PD-L2 results in suppression of T-cell effector 
function, which enables tumor cells expressing these 
ligands to avoid destruction by the immune system. 
Inhibition of PD-1 binding to PD-L1/PD-L2 has been 
shown to reverse this mechanism and has been as-
sociated with a response in several cancers, including 
cSCC (103). 
Cemiplimab
Cemiplimab was approved in September 2018 in 
the US for the treatment of patients with metastatic 
cSCC or locally advanced cSCC who are not candi-
dates for curative surgery or radiation (105,106). Ce-
miplimab is undergoing regulatory assessment in the 
EU for the same indication (104). 
The recommended dosage of cemiplimab is 350 
mg administered as an intravenous (IV) infusion over 
30 min once every 3 weeks until disease progression 
or the emergence of unacceptable toxicity (105).
Due to immune response inhibition, cemiplimab 
has the potential to cause immune-mediated adverse 
reactions that may be severe and potentially fatal. On 
this basis, patients receiving cemiplimab should be 
monitored for signs and symptoms of immune-me-
diated adverse reactions with prompt medical man-
agement when detected (105).
Approval of cemiplimab was based on the efficacy 
and safety demonstrated in the 2-phase study. 
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The phase 1 study was an open-label, multicenter 
study that involved patients with advanced solid-
tumor cancers (86). The primary end point was the 
safety and side-effect profile of cemiplimab. In the 
dose-escalation portion of the phase 1 study, a deep 
and durable response was observed in a patient with 
advanced cSCC (107). Adult patients with advanced 
cSCC were involved in the expansion cohorts of the 
phase 1 study (86).
The phase 2 study was a nonrandomized, global, 
pivotal study involving patients with advanced cSCC 
(86). This study was designed to involve adult patients 
who had metastatic cSCC with distant or regional 
metastasis or both (group 1), as well as adult patients 
who had locally advanced cSCC (group 2). The prima-
ry end point was the response rate (86). 
For both studies, secondary end points included 
DOR, PFS, overall survival, and toxic effects. The time 
point for the primary analysis was reached for the 
metastatic-disease cohort. The phase 2 study for lo-
cally advanced cSCC is ongoing.
Adult patients who had locally/regionally ad-
vanced disease with either recurrence after two or 
more surgical procedures or in whom surgery would 
result in substantial complications or deformity, as 
well as adult patients with metastatic cSCC were 
included (86). For both studies, key inclusion crite-
ria included Eastern Cooperative Oncology Group 
(ECOG) performance status of 0 or 1, adequate organ 
function, and at least one lesion measurable by Re-
sponse Evaluation Criteria In Solid Tumors (RECIST) 
v1.1.10.
Exclusion criteria were ongoing or recent (within 
5 years) autoimmune disease that was treated with 
systemic immunosuppressive therapy, previous treat-
ment with anti-PD-1 or anti-PD-L1 therapy, solid-or-
gan transplantation, or concurrent cancer, unless the 
disease was indolent or was not considered to be life-
threatening (e.g. BCC) (86).
The treatment regimen was an IV dose of ce-
miplimab (3 mg per kilogram of body weight, admin-
istered over a period of 30 minutes) every 2 weeks. 
The duration of treatment was up to 48 weeks in the 
phase 1 study and up to 96 weeks in the phase 2 study 
or until the patient had unacceptable toxic effects or 
had confirmed disease progression (86). 
In both studies, the patients were assessed for a 
response to cemiplimab every 8 weeks by means of 
imaging studies.
A total of 26 patients (10 with metastatic and 16 
with locally advanced cSCC) were enrolled in expan-
sion cohorts of the phase 1 study. Regarding previ-
ous treatments for cSCC, 58% had received previous 
systemic therapy and 77% previous radiotherapy. The 
median follow-up was 11.0 months (86). 
The ORR was 50%. The rate of durable disease con-
trol was 65%. The median observed time to response 
was 2.3 months. The DOR exceeded 6 months in 7 of 
the 13 patients who had a response (54%) (86).
The most common AEs of any grade were fatigue 
(27%), constipation, decreased appetite, diarrhea, 
hypercalcemia, hypophosphatemia, nausea, and 
urinary tract infection (each occurring in 15% of the 
patients) (86,108-110). There were 5 deaths: 3 due to 
disease progression, 1 due to an unknown cause, and 
1 due to an AE.
A total of 59 patients were enrolled in the meta-
static-disease cohort of the phase 2 study. Regarding 
previous treatments for cSCC, 56% had received pre-
vious systemic therapy and 85% previous radiothera-
py. The median follow-up was 7.9 months (86). 
The ORR was 47% and the rate of durable disease 
control was 61%. A PR was observed in 24 patients 
and a CR in 4 patients. The median observed time to 
response was 1.9 months. The median DOR had not 
been reached at the time of the analysis. However, 
the DOR exceeded 6 months in 16 of the 28 patients 
who had a response (57%) (86). 
At the time of data cutoff, 82% of patients contin-
ued to have a response and to receive cemiplimab. 
A response was observed in 49% of patients with 
distant metastasis and 43% of patients with regional 
metastasis (86). 
The most common AEs were diarrhea (27%), fa-
tigue (24%), nausea (17%), constipation (15%), and 
rash (15%) (86,108-110). Four patients (7%) discontin-
ued treatment because of an AE. Severe AEs (grade 
≥3) were cellulitis, pneumonitis, hypercalcemia, pleu-
ral effusion, and death. Overall, there were 11 deaths: 
8 due to disease progression and 3 due to AEs.
Severity of AEs was graded according to the CT-
CAE v4.03 (86). Most AEs related to the treatment 
were grade 1 or 2 events.
In conclusion, cemiplimab had similar efficacy for 
the treatment of metastatic and locally/regionally 
advanced cSCC. Final data from the cSCC expansion 
cohorts of the phase 1 study and metastatic-disease 
cohort of the phase 2 study show that cemiplimab 
demonstrated an acceptable risk/benefit profile with 
substantial antitumor activity (in approximately half 
the patients) and durability of responses. Concerning 
the side-effect profile, cemiplimab was associated 
with AEs that are similar to those seen with other PD-
1 inhibitors.
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Other targeted therapies for advanced 
cSCC
There are almost no data regarding the use of 
either the anti-CTLA4 antibody ipilimumab or other 
anti-PD-1 agents, such as nivolumab or pembroli-
zumab, for the treatment of cSCC. There are single 
case reports of anti-PD-1 therapy with nivolumab 
and pembrolizumab for advanced unresectable or 
metastatic cSCC demonstrating a clinical effect and 
tolerability (111-114), but their use in the treatment 
of advanced cSCC is still off-label.
Anti-EGFR therapies alone or in combination with 
chemotherapy and radiotherapy have demonstrated 
clinical benefits (94). Cetuximab and panitumumab 
are two monoclonal EGFR-targeting antibiodies that 
have been evaluated in cSCC. Cetuximab is a chime-
ric monoclonal IgG1 antibody that prevents ligand-
induced activation of EGFR and mediates a variety of 
antitumor activities (115). So far, the most important 
study in cSCC is a phase II trial of Maubec et al. (116), 
in which cetuximab was used as first-line single-drug 
therapy in 36 patients reaching a 69% disease control 
rate at week 6. Two CR and eight PR with acceptable 
skin toxicity have been achieved. In another report, 
neoadjuvant therapy with cetuximab alone or in 
combination with platinum salt and 5-FU have been 
proposed as a valid option for locally advanced cSCC 
(117). Cetuximab combined with radiotherapy has also 
shown interesting results in terms of response rate, 
disease-free survival, and overall survival (118,119).
Panitumumab demonstrated responses as a sin-
gle-agent in patients with locally advanced cSCC in a 
phase II study (120).
Oral agents targeting the EGFR pathway include 
gefitinib and erlotinib. Gefitinib, which affects the 
ATP-binding site of EGFR, inhibits autophosphoryla-
tion and receptor activation. In a small phase II neo-
adjuvant study in patients undergoing resection or 
radiotherapy, it demonstrated CR in 18.2% and PR in 
27.3% (121).
Similarly, erlotinib, another orally available EGFR 
inhibitor, has demonstrated responses in advanced 
cSCC alone (122) or in combination with other thera-
pies (123,124).
Generally, EGFR pathway inhibition is well toler-
ated but results in modest disease control. Another 
problem is resistance to EGFR inhibition which devel-
ops relatively rapidly (125). 
CONClUSION
Until recent years, advanced (inoperable) and 
metastatic forms of NMSCs were limited to palliative 
treatment options which offer modest clinical ben-
efit. Better understanding of the pathogenesis of 
these cancers, especially Hh signaling pathway and 
the role of immunosurveillence, has led to a break-
through in the development of novel targeted agents 
and immunotherapies which are decreasing morbid-
ity for those afflicted with refractory forms of NMSCs. 
Both HPI and immune checkpoint inhibitors have 
demonstrated satisfactory and sustainable antitumor 
activity with acceptable side-effect profiles. Howev-
er, there still remain important questions regarding 
long-term benefits, tolerability of adverse effects, and 
acquisition of resistant mutations over time. Further 
clinical trials and real-world data are needed to better 
characterize their practical value and make better-in-
formed treatment decisions. 
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